EE33 Cost-Effectiveness of Aducanumab, Lecanemab, and Donanemab for Early Alzheimer Disease in the US
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.334
https://www.valueinhealthjournal.com/article/S1098-3015(24)00449-2/fulltext
Title :
EE33 Cost-Effectiveness of Aducanumab, Lecanemab, and Donanemab for Early Alzheimer Disease in the US
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00449-2&doi=10.1016/j.jval.2024.03.334
First page :
Section Title :
Open access? :
No
Section Order :
11683